89Zr-labeled compounds for PET imaging guided personalized therapy

Drug Discovery Today: Technologies

Volumn 8, Issue 2-4, 2011, Pages

  Vugts, Danielle J ^a   Van Dongen, Guus A M S ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; DEFEROXAMINE; DIMETHYL SULFOXIDE; EDETIC ACID; GIRENTUXIMAB; IBRITUMOMAB TIUXETAN; IODINE 123; ISOTOPE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY J591; MONOCLONAL ANTIBODY U 36; RANIBIZUMAB; SUNITINIB; TECHNETIUM 99M; TRASTUZUMAB; UNCLASSIFIED DRUG; YTTRIUM; ZIRCONIUM 89; ZIRCONIUM DERIVATIVE;

CHELATION; COMPUTER ASSISTED TOMOGRAPHY; DENSITY FUNCTIONAL THEORY; DOWN REGULATION; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG PURIFICATION; DRUG STABILITY; DRUG SYNTHESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEASIBILITY STUDY; GOOD MANUFACTURING PRACTICE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYDROLYSIS; IMAGE ANALYSIS; IMAGE QUALITY; IMMUNOAFFINITY CHROMATOGRAPHY; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; IRRADIATION; ISOTOPE LABELING; KIDNEY; LIVER; LYMPH NODE METASTASIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATION; PERSONALIZED MEDICINE; PH; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; RADIATION DOSE; RADIOACTIVITY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 84861227731     PISSN: None     EISSN: 17406749     Source Type: Journal    
DOI: 10.1016/j.ddtec.2011.12.004     Document Type: Review

References (36)

1. van Dongen, G.A.M.S. and Vosjan, M.J.W.D. (2010) Immuno-positron emission tomography: shedding light on clinical antibody therapy. Cancer Biother. Radiopharm. 25, 375-385
2. McCabe, K.E. and Wu, A.M. (2010) Positive progress in immunoPET - not just a coincidence. Cancer Biother. Radiopharm. 25, 253-261
3. Nayak, T. and Brechbiel, M.W. (2009) Radioimmunoimaging with longerlived positron-emitting radionuclides: potentials and challenges. Bioconjug. Chem. 20, 825-841
4. Ikotun, F.O. and Lapi, S.E. (2011) The rise of metal radionuclides in medical imaging: copper-64, zirconium-89 and yttrium-86. Future Med. Chem. 3, 599-621
5. Wadas, T.J. et al. (2010) Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease. Chem. Rev. 110, 2858-2902
6. Zeglis, B.M. and Lewis, J.S. (2011) A practical guide to the construction of radiometallated bioconjugates for positron emission tomography. Dalton Trans. 40, 6168-6195
7. Meijs, W.E. et al. (1994) Production of highly pure no-carrier added 89Zr for the labeling of antibodies with a positron emitter. Appl. Radiat. Isot. 45, 1143-1147
8. Verel, I. et al. (2003) 89Zr Immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies. J. Nucl. Med. 44, 1271-1281 (Pubitemid 39662684)
9. Holland, J.P. et al. (2009) Standardized methods for the production of high specific-activity zirconium-89. Nucl. Med. Biol. 36, 729-739
10. Baroncelli, F. and Grossi, G. (1965) The complexing power of hydroxamic acids and its effect on the behaviour of organic extractants in the reprocessing of irradiated fuels - I: the complexes between benzohydroxamic acid and zirconium, iron (III) and uranium (VI). J. Inorg. Nucl. Chem. 27, 1085-1092
11. Fouché, K.F. et al. (1970) Complex formation of Zr(IV) and Hf(IV) with hydroxamic acids in acidic solutions. J. Inorg. Nucl. Chem. 32, 1949-1962
12. Holland, J.P. et al. (2010) 89Zr-DFO-J591 for immunoPET of prostatespecific membrane antigen expression in vivo. J. Nucl. Med. 51, 1293-1300
13. Lindmo, T. et al. (1984) Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J. Immunol. Methods 72, 77-89 (Pubitemid 14091996)
14. Meijs, W.E. et al. (1996) A facile method for the labeling of proteins with zirconium isotopes. Nucl. Med. Biol. 23, 439-448 (Pubitemid 26233214)
15. Meijs, W.E. et al. (1997) Zirconium-labeled monoclonal antibodies and their distribution in tumor-bearing nude mice. J. Nucl. Med. 38, 112-118 (Pubitemid 27027011)
16. Verel, I. et al. (2003) Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice. J. Nucl. Med. 44, 1663-1670 (Pubitemid 40003744)
17. Verel, I. et al. (2003) Long-lived positron emitters zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates with PET. Cancer Biother. Radiopharm. 18, 655-661 (Pubitemid 37082386)
18. Brouwers, A. et al. (2004) PET radioimmunoscintigraphy of renal cell cancer using 89Zr-labeled cG250 monoclonal antibody in nude rats. Cancer Biother. Radiopharm. 19, 155-163 (Pubitemid 38685113)
19. Perk, L.R. et al. (2005) 89Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals 90Y and 177Lu in tumorbearing nude mice after coupling to the internalizing antibody cetuximab. J. Nucl. Med. 46, 1898-1906 (Pubitemid 46196653)
20. Perk, L.R. et al. (2006) Preparation and evaluation of 89Zr-Zevalin for monitoring of 90Y-Zevalin biodistribution with positron emission tomography. Eur. J. Nucl. Med. Mol. Imag. 33, 1337-1345 (Pubitemid 44630790)
21. Nagengast, W.B. et al. (2007) In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J. Nucl. Med. 48, 1313-1319 (Pubitemid 47242797)
22. Perk, L.R. et al. (2008) Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30. Eur. J. Nucl. Med. Mol. Imaging 35, 1857-1867
23. Dijkers, E.C.F. et al. (2009) Development and characterization of clinicalgrade 89Zr-trastuzumab for HER2/neu immunoPET imaging. J. Nucl. Med. 50, 974-981
24. Aerts, H.J.W.L. et al. (2009) Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET. J. Nucl. Med. 50, 123-131
25. Oude Munnink, T.H. et al. (2010) 89Zr-trastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVP-AUY922 in a human tumour xenograft. Eur. J. Cancer 46, 678-684
26. Nagengast, W.B. et al. (2010) 89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVPAUY922. J. Nucl. Med. 51, 761-767
27. Heskamp, S. et al. (2010) ImmunoSPECT and immunoPET of IGF-1R expression with the radiolabeled antibody R1507 in a triple-negative breast cancer model. J. Nucl. Med. 51, 1565-1572
28. Hoeben, B.A.W. et al. (2010) PET of hypoxia with 89Zr-labeled cG250- F(ab')2 in head and neck tumors. J. Nucl. Med. 51, 1076-1083
29. Holland, J.P. et al. (2010) Measuring the pharmacodynamic effect of a novel Hsp90 inhibitor on HER2/neu expression in mice using 89Zr-DFO- trastuzumab. PLoS ONE 5, e8859
30. Nagengast, W.B. et al. (2011) VEGF-PET imaging is a noninvasive biomarker showing differential changes in the tumor during sunitinib treatment. Cancer Res. 71, 143-153
31. Börjesson, P.K.E. et al. (2006) Performance of immuno-positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients. Clin. Cancer Res. 12, 2133-2140
32. Börjesson, P.K.E. et al. (2009) Radiation dosimetry of 89Zr-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients. J. Nucl. Med. 50, 1828-1836
33. Dijkers, E.C. et al. (2010) Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin. Pharmacol. Ther. 87, 586-592
34. Vosjan, M.J.W.D. et al. (2010) Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyldesferrioxamine. Nat. Prot. 5, 739-743
35. Perk, L.R. et al. (2010) p-Isothiocyanatobenzyldesferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging. Eur. J. Nucl. Med. Mol. Imaging 37, 250-259
36. Tinianow, J.N. et al. (2010) Site-specifically 89Zr-labeled monoclonal antibodies for immunoPET. Nucl. Med. Biol. 37, 289-297